UBS Raises Cardinal Health (CAH) Price Target to $295
UBS has reiterated its Buy rating on Cardinal Health, raising the price target to $295, a 16.86% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
UBS raised its price target on Cardinal Health, Inc. ($CAH) to $295 from $280 on October 16, 2026, and rates the stock "Buy".
CAH
Cardinal Health, Inc.
Key Points
- On October 16, 2026, UBS reiterated its Buy rating on Cardinal Health, Inc. (CAH) and raised the price target from $280 to $295.
- UBS's $295 price target implies 16.86% upside from Cardinal Health, Inc.'s ($CAH) current $252.44 share price.
- The recent trading price of Cardinal Health is $252.44, which is about 14.4% below UBS's new target.
- Cardinal Health has a trailing twelve-month revenue of $254.2 billion and is set to report earnings on November 5, 2026.
Get $CAH trade alerts by text
We text you when insiders, Congress or big funds trade $CAH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cardinal Health, Inc. alert may contain errors. Disclosures
UBS has reiterated its Buy rating on Cardinal Health, Inc. (CAH) on October 16, 2026, and raised its price target from $280 to $295. This adjustment comes as the stock recently traded around $252.44, placing it about 14.4% below UBS's updated target.
UBS vs. the S&P 500
Hypothetical returns from UBS's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Cardinal Health
Several other institutional investors have made notable changes in their positions regarding Cardinal Health. Blackrock Inc. reduced its stake by 2,003,110 shares, bringing its total to 26,490,633 shares worth approximately $6.73 billion. In contrast, Wellington Management Group, LLP increased its holdings by 10,584,180 shares, ending with 14,860,271 shares valued at about $3.78 billion. Vanguard Capital Management LLC made a minor addition of 3,058 shares, resulting in a total of 15,292,186 shares worth around $3.89 billion.
Cardinal Health, Inc. Stock Down 0.5%
Cardinal Health's stock is currently trading at $252.44, which is near the lower end of its recent trading range. The stock's performance is significant as it is positioned below UBS's target of $295, suggesting potential upside if the target is reached.
$CAH price target
Cardinal Health, Inc. daily closes and this analyst's $295 target. Not advice.
Recent Earnings
For the trailing twelve months, Cardinal Health reported revenue of approximately $254.2 billion and an earnings per share (EPS) of $7.23. The company has a net margin of 0.7% and a year-over-year revenue growth of 5.8%. The next earnings report is scheduled for November 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at Cardinal Health, Inc.
Recent insider trading activity includes several notable sales. On August 18, 2026, Officer Stephen M Mason sold 35,000 shares, valued at approximately $8.27 million. Chief Technology Officer Michelle D Greene sold 11,650 shares, totaling around $2.75 million. Additionally, on August 19, 2026, CEO Jason M Hollar sold 124,529 shares worth about $29.38 million. These transactions were not part of planned sales.
Analysts Set New Price Targets
On October 16, 2026, UBS maintained its Buy rating on Cardinal Health with a new price target of $295, up from $280. This comes after several firms, including TD Cowen and Barclays, also maintained their ratings, indicating a generally positive outlook on the stock.
About Cardinal Health
Cardinal Health, Inc. is a healthcare services and products company. It operates in two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for various healthcare providers, including hospitals and pharmacies, which is vital for its continued growth and stability in the healthcare sector.
Bottom Line
Looking ahead, investors should keep an eye on Cardinal Health's upcoming earnings report on November 5, 2026, and any further updates from analysts regarding price targets. UBS's reiterated Buy rating and increased target suggest a positive outlook for the company despite the recent trading price.
Related Filing Alerts
Source: UBS's rating change on $CAH (Oct 16, 2026). Written by software, not financial advice. How we make alerts